A Research Study Looking at How Well a Combination of the Medicines Semaglutide and NNC0480-0389 Works in People With Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Registration Number
- NCT05144984
- Lead Sponsor
- Novo Nordisk A/S
- Brief Summary
This study is looking at semaglutide in combination with a potential new medicine (NNC0480-0389) in people with type 2 diabetes.
The study is being conducted to see how well semaglutide, in combination with different doses of NNC0480-0389, work to lower blood sugar levels. Results from this study will be used to select the doses of the two medicines for other studies.
Participants will either get:
Semaglutide (a medicine doctors can already prescribe for treatment of type 2 diabetes) in combination with NNC0480-0389 (a potential new medicine) or placebo (a 'dummy' medicine that looks like the medicines but without any medicine).
NNC0480-0389 alone, or semaglutide alone which treatment participant get is decided by chance.
Participant will need to take 2-3 injections once every week during the study. One injection will be with semaglutide or placebo and 1-2 injections will be with NNC0480-0389 or placebo.
Participant must inject the study medicines themself into the stomach, thigh, or upper arm.
The study will last for about 41weeks. Participant will have 20 clinic visits. Participant will have blood samples taken at all clinic visits. At 3 clinic visits, participant will also have an electrocardiogram (ECG). This is a test to check participants heart. Participant will have their eyes checked before or at the start of the study and at the end of the study.
Women can only take part in the study if they are not able to become pregnant
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 500
- Diagnosed with type 2 diabetes mellitus greater than or equal to 180 days before screening
- Participants treated with diet and exercise as monotherapy or in combination with stable daily dose(s) greater than or equal to 90 days before screening of any metformin formulations greater than or equal to 1500 mg or maximum tolerated or effective dose
- HbA1c 7.0-10.0% (53-86 mmol/mol) (both inclusive)
- BMI greater than or equal to 25 and below 40 kg/m^2
- Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 days and prior insulin treatment for gestational diabetes are allowed
- Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination
- Presence or history of any clinically relevant respiratory, metabolic, renal, hepatic cardiovascular, gastrointestinal, or endocrinological conditions (except conditions associated with T2D)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description NNC0480-0389 + placebo (semaglutide) NNC0480-0389 subjects will receive once weekly subcutaneous (s.c., under the skin) dose of NNC0480-0389 co-administered with s.c. placebo (semaglutide) Placebo (semaglutide) + placebo ( 2.4 mg NNC0480-0389) Placebo (NNC080-0389) subjects will receive once weekly subcutaneous (s.c., under the skin) dose of placebo (NNC0480-0389) co-administered with s.c. placebo (semaglutide). Placebo (semaglutide) + placebo ( 2.4 mg NNC0480-0389) Placebo (semaglutide) subjects will receive once weekly subcutaneous (s.c., under the skin) dose of placebo (NNC0480-0389) co-administered with s.c. placebo (semaglutide). 2.4 mg semaglutide + 7.2 mg NNC0480-0389 NNC0480-0389 subjects will receive once weekly subcutaneous (s.c., under the skin) dose of NNC0480-0389 co-administered with s.c. semaglutide 2.4 mg semaglutide + 12.0 mg NNC0480-0389 NNC0480-0389 subjects will receive once weekly subcutaneous (s.c., under the skin) dose of NNC0480-0389 co-administered with s.c. semaglutide 2.4 mg semaglutide + 21.6 mg NNC0480-0389 NNC0480-0389 subjects will receive once weekly subcutaneous (s.c., under the skin) dose of NNC0480-0389 co-administered with s.c. semaglutide NNC0480-0389 + placebo (semaglutide) Placebo (semaglutide) subjects will receive once weekly subcutaneous (s.c., under the skin) dose of NNC0480-0389 co-administered with s.c. placebo (semaglutide) 2.4 mg semaglutide + 2.4 mg NNC0480-0389 NNC0480-0389 subjects will receive once weekly subcutaneous (s.c., under the skin) dose of NNC0480-0389 co-administered with s.c. semaglutide. Placebo (semaglutide) + placebo ( 7.2 mg NNC0480-0389) Placebo (NNC080-0389) subjects will receive once weekly subcutaneous (s.c., under the skin) dose of placebo (NNC0480-0389) co-administered with s.c. placebo (semaglutide). Placebo (semaglutide) + placebo ( 12.0 mg NNC0480-0389) Placebo (NNC080-0389) subjects will receive once weekly subcutaneous (s.c., under the skin) dose of placebo (NNC0480-0389) co-administered with s.c. placebo (semaglutide). Placebo (semaglutide) + placebo ( 12.0 mg NNC0480-0389) Placebo (semaglutide) subjects will receive once weekly subcutaneous (s.c., under the skin) dose of placebo (NNC0480-0389) co-administered with s.c. placebo (semaglutide). Placebo (semaglutide) + placebo ( 7.2 mg NNC0480-0389) Placebo (semaglutide) subjects will receive once weekly subcutaneous (s.c., under the skin) dose of placebo (NNC0480-0389) co-administered with s.c. placebo (semaglutide). Placebo (semaglutide) + placebo ( 21.6 mg NNC0480-0389) Placebo (NNC080-0389) subjects will receive once weekly subcutaneous (s.c., under the skin) dose of placebo (NNC0480-0389) co-administered with s.c. placebo (semaglutide). Placebo (semaglutide) + placebo ( 21.6 mg NNC0480-0389) Placebo (semaglutide) subjects will receive once weekly subcutaneous (s.c., under the skin) dose of placebo (NNC0480-0389) co-administered with s.c. placebo (semaglutide). Semaglutide 2.4 mg + placebo (NNC0480-0389) Placebo (NNC080-0389) subjects will receive once weekly subcutaneous (s.c., under the skin) dose of placebo (NNC0480-0389) co-administered with s.c. semaglutide. 2.4 mg semaglutide + 2.4 mg NNC0480-0389 Semaglutide subjects will receive once weekly subcutaneous (s.c., under the skin) dose of NNC0480-0389 co-administered with s.c. semaglutide. 2.4 mg semaglutide + 7.2 mg NNC0480-0389 Semaglutide subjects will receive once weekly subcutaneous (s.c., under the skin) dose of NNC0480-0389 co-administered with s.c. semaglutide 2.4 mg semaglutide + 12.0 mg NNC0480-0389 Semaglutide subjects will receive once weekly subcutaneous (s.c., under the skin) dose of NNC0480-0389 co-administered with s.c. semaglutide 2.4 mg semaglutide + 21.6 mg NNC0480-0389 Semaglutide subjects will receive once weekly subcutaneous (s.c., under the skin) dose of NNC0480-0389 co-administered with s.c. semaglutide Semaglutide 2.4 mg + placebo (NNC0480-0389) Semaglutide subjects will receive once weekly subcutaneous (s.c., under the skin) dose of placebo (NNC0480-0389) co-administered with s.c. semaglutide.
- Primary Outcome Measures
Name Time Method Change in HbA1c From baseline (week 0) to visit 24 (week 34) percentage-point
- Secondary Outcome Measures
Name Time Method Change in fasting plasma glucose (FPG) From baseline (week 0) to visit 24 (week 34) measured in mmol/L
Change in body weight (kg) From baseline (week 0) to visit 24 (week 34) measured in kg
Relative change in low-density lipoprotein (LDL) cholesterol From baseline (week 0) to visit 24 (week 34) ratio
Relative change in triglycerides From baseline (week 0) to visit 24 (week 34) ratio
Change in body weight (%) From baseline (week 0) to visit 24 (week 34) measured in percent
Change in waist circumference From baseline (week 0) to visit 24 (week 34) measured in cm
Change in systolic blood pressure (SBP) From baseline (week 0) to visit 24 (week 34) measured in mmHg
Relative change in total cholesterol From baseline (week 0) to visit 24 (week 34) ratio
Relative change in high-density lipoprotein (HDL) cholesterol From baseline (week 0) to visit 24 (week 34) ratio
Relative change in very-low-density lipoprotein (VLDL) cholesterol From baseline (week 0) to visit 24 (week 34) ratio
Relative change in Apolipoprotein B (ApoB) From baseline (week 0) to visit 24 (week 34) ratio
Relative change in high sensitivity C-Reactive Protein (hsCRP) From baseline (week 0) to visit 24 (week 34) ratio
Relative change in free fatty acids From baseline (week 0) to visit 24 (week 34) ratio
Number of treatment-emergent adverse events (TEAEs) From baseline (week 0) to visit 25 (week 39) Count of events
Trial Locations
- Locations (89)
Velocity Clin Res-Chula Vista
🇺🇸Chula Vista, California, United States
Headlands Research California, LLC
🇺🇸Escondido, California, United States
St. Jos Heritage Hlthcr_Fllrtn
🇺🇸Fullerton, California, United States
Velocity Clinical Research San Diego
🇺🇸La Mesa, California, United States
First Valley Med Grp Lancaster
🇺🇸Lancaster, California, United States
Torrance Clin Res Inst, Inc.
🇺🇸Lomita, California, United States
Velocity Clin Res Wstlke
🇺🇸Los Angeles, California, United States
Valley Clinical Trials, Inc.
🇺🇸Northridge, California, United States
Artemis Insitute for Clin Res
🇺🇸Riverside, California, United States
Artemis Institute for Clin Res
🇺🇸San Diego, California, United States
Scroll for more (79 remaining)Velocity Clin Res-Chula Vista🇺🇸Chula Vista, California, United States